

April 16, 2021

For Immediate Release

VIVIMED PRODUCT APPROVALS

Hyderabad, India, April 16,2021 – Vivimed Labs Limited ("Vivimed" or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today that it received approvals for 3 products from its state of the art manufacturing site in Hyderabad, which is PICS & Health Canada approved site.

1. Bilastine tablets 20mg under brand name FLUSTIN

Uses:

Bilastine is a second-generation antihistamine (a selective histamine H1 receptor antagonist).

It is used in the treatment of allergic Rhinoconjunctivitis and Urticaria (hives).

2. Ornidazole and Ofloxacin tablets under brand name ORZOLE COMBI

Uses:

Ornidazole 500mg + Ofloxacin 200mg tablets is used in the treatment of bacterial & parasitic infections.

It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections.

3. Paracetamol 125mg/5ml and Chlorpheniramine Maleate Syrup 2mg/5ml 100ml under brand name FEBRIL

Uses:

Paracetamol, also known as acetaminophen, is a medication used to treat fever and mild to moderate pain.

Chlorpheniramine Maleate, is an antihistamine used to treat the symptoms of allergic conditions such as allergic rhinitis.

Menthol is a topical analgesic. It works by temporarily relieving minor pain.

*** *** ***

Commenting on the Approvals, Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "These 3 approvals are testimony to high quality team work of Vivimed's end to end team. Branded exports is strategic thrust of 'New and Vibrant Vivimed'. The approvals are testimony to Vivimed's growth strategy".

For VIVIMED LABS LTD carc GANDHAR **Company Secretary** ACS No. 19315

For further information on Vivimed, visit www.vivimedlabs.com

*** *** ***

Safe Harbour

This release contains "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed's future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact: **Company Contact:** Kopparthi Yugandhar Company Secretary & Compliance officer Vivimed Labs Limited (CIN No: L02411KA1988PLC009465) Corporate office: Northend Complex, Road No.2,Banjara Hills, Hyderabad, India Phone: 040-66086608, Email: yugandhar.kopparthi@vivimedlabs.com

For VIVIMED LABS LTD. uga NDHAR Company Secretary ACS No. 19315